Comparison of Dalbavancin MIC Values Determined by Etest (AB BIODISK) and Reference Dilution Methods Using Gram-Positive Organisms-Reference-Cited by-同舟云学术

Comparison of Dalbavancin MIC Values Determined by Etest (AB BIODISK) and Reference Dilution Methods Using Gram-Positive Organisms

Published:2006-08 Issue:8 Volume:44 Page:2988-2990
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Fritsche Thomas R.¹,Rennie Robert P.²,Goldstein Beth P.³,Jones Ronald N.¹⁴

Affiliation:

1. JMI Laboratories, North Liberty, Iowa

2. University of Alberta Hospital, Edmonton, Alberta, Canada

3. Pfizer, Inc., New York, New York

4. Tufts University School of Medicine, Boston, Massachusetts

Abstract

ABSTRACT While standardized microdilution testing methodologies and quality control ranges exist for the novel glycolipopeptide dalbavancin, no testing methods have been described that are immediately available for routine use in clinical laboratories. In this study, we found that the dalbavancin Etest (AB BIODISK, Solna, Sweden) procedure demonstrated a high degree of agreement (100% within ±2 log 2 dilution steps) with the standardized broth microdilution method, validating the use of the Etest as an alternative test for investigational or clinical purposes following regulatory approval.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.00640-06

Reference14 articles.

1. Initial Quality Control Evaluations for Susceptibility Testing of Dalbavancin (BI397), an Investigational Glycopeptide with Potent Gram-Positive Activity

2. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing 16th informational supplement. M100-S16. Clinical and Laboratory Standards Institute Wayne Pa.

3. Ellis, M. W., and J. S. Lewis II. 2005. Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections. Curr. Opin. Infect. Dis.18:496-501.

4. Jauregui, L. E., S. Babazadeh, E. Seltzer, L. Goldberg, D. Krievins, M. Frederick, D. Krause, I. Satilovs, Z. Endzinas, J. Breaux, and W. O'Riordan. 2005. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis.41:1407-1415.

5. Jones, R. N., J. M. Streit, and T. R. Fritsche. 2004. Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. Int. J. Antimicrob. Agents23:197-199.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Don't Be So Negative; Let's Have a Positive Perspective! A Review of Novel Antibiotics Targeting Gram-Positive Bacteria;Clinical Microbiology Newsletter;2022-12

2. Antimicrobial Susceptibility Testing for Enterococci;Journal of Clinical Microbiology;2022-09-21

3. New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides;Antimicrobial Agents and Chemotherapy;2022-06-21

4. Accuracy of gradient diffusion method for susceptibility testing of dalbavancin and comparators;Expert Review of Anti-infective Therapy;2021-09-11

5. Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review;Antibiotics;2021-05-31